BIOLARGO, INC. financial data

Symbol
BLGO on OTC
Location
Westminster, CA
Fiscal year end
31 December
Latest financial report
10-K - Q4 2025 - 04 Mar 2026

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 171% % -27%
Quick Ratio 9.6% % 18%
Debt-to-equity 91% % 63%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 319,750,855 shares 6.1%
Entity Public Float $63,071,415 USD 2.7%
Common Stock, Value, Issued $213,000 USD 5.4%
Weighted Average Number of Shares Outstanding, Basic 306,954,778 shares 3%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense $2,593,000 USD -10%
Operating Income (Loss) $14,855,000 USD -243%
Nonoperating Income (Expense) $334,000 USD -1988%
Earnings Per Share, Basic -0.04 USD/shares -300%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $3,883,000 USD 9.4%
Accounts Receivable, after Allowance for Credit Loss, Current $615,000 USD -81%
Inventory, Net $310,000 USD -6.1%
Assets, Current $5,114,000 USD -28%
Property, Plant and Equipment, Net $1,643,000 USD -5.7%
Operating Lease, Right-of-Use Asset $1,028,000 USD 3.6%
Other Assets, Noncurrent $106,000 USD 12%
Assets $8,311,000 USD -21%
Accounts Payable, Current $1,012,000 USD 23%
Employee-related Liabilities, Current $199,000 USD 66%
Contract with Customer, Liability, Current $280,000 USD
Liabilities, Current $5,063,000 USD 91%
Operating Lease, Liability, Noncurrent $864,000 USD -6.3%
Liabilities $6,785,000 USD 52%
Accumulated Other Comprehensive Income (Loss), Net of Tax $207,000 USD -13%
Retained Earnings (Accumulated Deficit) $161,280,000 USD -7.9%
Stockholders' Equity Attributable to Parent $4,042,000 USD -54%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest $1,526,000 USD -75%
Liabilities and Equity $8,311,000 USD -21%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $1,830,000 USD -480%
Net Cash Provided by (Used in) Financing Activities $866,000 USD -20%
Net Cash Provided by (Used in) Investing Activities $0 USD
Common Stock, Shares Authorized 550,000,000 shares 0%
Common Stock, Shares, Issued 317,377,777 shares 5.3%
Common Stock, Par or Stated Value Per Share 0.0007 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $984,000 USD -223%
Interest Paid, Excluding Capitalized Interest, Operating Activities $37,000 USD 208%
Deferred Tax Assets, Valuation Allowance $19,994,000 USD -11%
Operating Lease, Liability $1,074,000 USD 4.6%
Depreciation $145,000 USD -6.5%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $11,804,000 USD -411%
Lessee, Operating Lease, Liability, to be Paid $1,686,000 USD -4.5%
Property, Plant and Equipment, Gross $2,250,000 USD 2.1%
Operating Lease, Liability, Current $210,000 USD 100%
Lessee, Operating Lease, Liability, to be Paid, Year Two $335,000 USD 16%
Lessee, Operating Lease, Liability, to be Paid, Year One $384,000 USD 36%
Operating Lease, Weighted Average Discount Rate, Percent 0.18 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $612,000 USD -17%
Lessee, Operating Lease, Liability, to be Paid, Year Three $226,000 USD -24%
Deferred Tax Assets, Operating Loss Carryforwards $19,994,000 USD -11%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 50,000,000 shares 0%
Unrecognized Tax Benefits $0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four $231,000 USD -5.7%
Additional Paid in Capital $165,316,000 USD 4.4%
Preferred Stock, Shares Outstanding 0 shares
Interest Expense $45,000 USD -47%
Preferred Stock, Par or Stated Value Per Share 0.0007 USD/shares 0%